Propylthiouracil hepatitis: Report of a case and extensive review of the literature

Journal of Pediatric Endocrinology and Metabolism

Volumn 25, Issue 3-4, 2012, Pages 331-343

  Memi, Eleni ^a   Karras, Spiros ^a   Tzotzas, Themistoklis ^a   Krassas, Gerasimos E ^a  

^a PANAGIA GENERAL HOSPITAL   (Greece)

Author keywords

adolescents; children; hepatitis; methimazole; propylthiouracil; thyrotoxicosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; POTASSIUM PERCHLORATE; PREDNISONE; PROPRANOLOL; PROPYLTHIOURACIL; RADIOACTIVE IODINE; SODIUM PERCHLORATE; THIAMAZOLE; THIONAMIDE; VITAMIN K GROUP;

ACUTE GLOMERULONEPHRITIS; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTHRITIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; BLISTER; CASE REPORT; CHILD; CHOLESTASIS; COHORT ANALYSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOGRAPHY; ERYTHEMA MULTIFORME; FATIGUE; FEMALE; FEVER; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GASTROINTESTINAL INFECTION; GRANULOCYTOPENIA; GRAVES DISEASE; HEMATURIA; HEPATITIS; HUMAN; HYPERAMMONEMIA; HYPERTHYROIDISM; INFLAMMATORY CELL; JAUNDICE; LEUKOPENIA; LITERATURE; LIVER BIOPSY; LIVER FAILURE; LIVER FUNCTION TEST; MOUTH ULCER; NAUSEA; NEPHRITIS; PHARYNGITIS; PROTHROMBIN TIME; PRURITUS; RASH; REVIEW; RHEUMATIC FEVER; SCHOOL CHILD; SORE THROAT; THROMBOCYTOPENIA; THYROID CARCINOMA; THYROIDECTOMY; URTICARIA; VASCULITIS; VOMITING;

ANTITHYROID AGENTS; CHILD; FEMALE; GRAVES DISEASE; HEPATITIS; HUMANS; LIVER FUNCTION TESTS; PROPYLTHIOURACIL; REVIEW LITERATURE AS TOPIC; VITAMIN K;

EID: 84861630535     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/jpem-2011-0442     Document Type: Review

References (63)

1. Landau RL. Landmark perspective: Treatment of hyperthyroidism. J Am Med Assoc 1984;251:1747-8.
2. Astwood EB. Landmark article May 8, 1943: Treatment of hyperthyroidism with thiourea and thiouracil. J Am Med Assoc 1984;251:1743-6.
3. Rivkees SA, Mattison DR. Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol 2009;2009:132041.
4. Moore FD. Toxic manifestations of thiouracil therapy. J Am Med Assoc 1946;130:315-9.
5. Livingston HJ, Livingston SF. Agranulocytosis and hepatocellular jaundice: Toxic reactions following propylthiouracil therapy. J Am Med Assoc 1947;135:422-5.
6. Rivkees SA, Szarfman A. Dissimilar hepatoxicity profiles of propylthiouracil and methimazole on children. J Clin Endocrinol Metab 2010;95:3260-7.
7. Eunice Kennedy Shriver National Institute of Child Health and Human Development. Hepatic toxicity following treatment for pediatric Graves'disease. Minutes of October 28 2008 meeting. Available at: Http://bpca.nichd.nih.gov/ outreach/index.cfm.
8. Rivkees SA. 63 years and 715 days to the "boxed warning" : Unmasking of the propylthiouracil problem. Int J Pediatr Endocrinol 2010;2010:658267.
9. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med 2009;360:1574-5.
10. Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, et al. The role of propylthiouracil in the management of Graves'disease in adults: Report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009;19:673-4.
11. Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, et al. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000;85:3678-82.
12. Vitug AC, Goldman JM. Hepatotoxicity from antithyroid drugs. Horm Res 1985;21:229-34.
13. Garty BZ, Kauli R, Ben-Ari J, Lubin E, Nitzan M, et al. Hepatitis associated with propylthiouracil treatment. Drug Intell Clin Pharm 1985;19:740-2.
14. Bloch CA, Jenski LJ, Balistreri WF, Dolan LM. Propylthiouracilassociated hepatitis. Arch Intern Med 1985;145:2129-30.
15. Levy M. Propylthiouracil hepatotoxicity. A review and case presentation. Clin Pediatr (Phila) 1993;32:25-9.
16. Hanson JS. Propylthiouracil and hepatitis. Two cases and a review of the literature. Arch Intern Med 1984;144:994-6.
17. Parker LN. Letter: Hepatitis and propylthiouracil. Ann Intern Med 1975;82:228-9.
18. Reddy CM. Propylthiouracil and hepatitis: A case report. J Natl Med Assoc 1979;71:1185-6.
19. Jonas MM, Eidson MS. Propylthiouracil hepatotoxicity: Two pediatric cases and review of the literature. J Pediatr Gastroenterol Nutr 1988;7:776-9.
20. Baker B, Shapiro B, Fig LM, Woodbury D, Sisson JC, et al. Unusual complications of antithyroid drug therapy: Four case reports and review of literature. Thyroidology 1989;1:17-26.
21. Maggiore G, Larizza D, Lorini R, De Giacomo C, Scotta MS, et al. Propylthiouracil hepatotoxicity mimicking autoimmune chronic active hepatitis in a girl. J Pediatr Gastroenterol Nutr 1989;8:547-8.
22. Kirkland JL. Propylthiouracil-induced hepatic failure and encephalopathy in a child. DICP 1990;24:470-1.
23. Deidiker R, deMello DE. Propylthiouracil-induced fulminant hepatitis: Case report and review of the literature. Pediatr Pathol Lab Med 1996;16:845-52.
24. Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of experience with propylthiouracil-associated hepatotoxicity: What have we learned? J Clin Endocrinol Metab 1997;82:1727-33.
25. Parolin MB, Lopes RW, Telles JE, Ioshii SO, Hajar N. Acute cholestatic hepatitis induced by propylthiouracil. Case report. Arq Gastroenterol 2000;37:129-32.
26. Testa G, Trevino J, Bogetti D, Layden T, Wiley T, et al. Liver transplantation for propylthiouracil-induced acute hepatic failure. Dig Dis Sci 2003;48:190-1.
27. Sipe WE, Su M, Posselt A, Kim GE, Quiros JA, et al. Propylthiouracil- associated liver failure presenting as probable autoimmune hepatitis in a child with Graves'disease. Pediatr Transplant 2006;10:525-8.
28. Bin-Abbas BS, Shabib SM, Al-Dekhail WM, Al-Shanafey SN, Al-Mehaideb AI, et al. Spontaneous recovery of propylthiouracilinduced fulminant hepatic failure in an 8-year old child. Saudi Med J 2007;28:804-6.
29. Root AW, Bongiovanni AM, Harvie FH, Eberlein WR. Treatment of juvenile thyrotoxicosis. J Pediatr 1963;63:402-7.
30. Amrhein JA, Kenny FM, Ross D. Granulocytopenia, lupus-like syndrome, and other complications of propylthiouracil therapy. J Pediatr 1970;76:54-63.
31. Barnes HV, Blizzard RM. Antithyroid drug therapy for toxic diffuse goiter (Graves disease): Thirty years experience in children and adolescents. J Pediatr 1977;91:313-20.
32. Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985;60:1019-24.
33. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: Twenty-five percent remission every two years. J Clin Endocrinol Metab 1987;64:1241-5.
34. Ward L, Huot C, Lambert R, Deal C, Collu R, et al. Outcome of pediatric Graves'disease after treatment with antithyroid medication and radioiodine. Clin Invest Med 1999;22:132-9.
35. Somnuke PH, Pusuwan P, Likitmaskul S, Santiprabhob J, Sawathiparnich P. Treatment outcome of Graves'disease in Thai children. J Med Assoc Thai 2007;90:1815-20.
36. Glaser NS, Styne DM, Organization of Pediatric Endocrinologists of Northern California Collaborative Graves'Disease Study Group. Predicting the likelihood of remission in children with Graves'disease: A prospective, multicenter study. Pediatrics 2008;121:e481-8.
37. Ma C, Kuang A, Xie J, Liu G. Radioiodine treatment for pediatric Graves'disease. Cochrane Database Syst Rev 2008;CD006294.
38. Sato H, Minagawa M, Sasaki N, Sugihara S, Kazukawa I, et al. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves'disease: Efficacy and adverse reactions during initial treatment and long-term outcome. J Pediatr Endocrinol Metab 2011;24:257-63.
39. Livadas S, Xyrafis X, Economou F, Boutzios G, Christou M, et al. Liver failure due to antithyroid drugs: Report of a case and literature review. Endocrine 2010;38:24-8.
40. Liaw YF, Huang MJ, Fan KD, Li KL, Wu SS, et al. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann Intern Med 1993;118:424-8.
41. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905-17.
42. Lian XL, Bai Y, Dai WX, Guo ZS, Li W, et al. Propylthiouracilinduced overt hepatic injury in patients with hyperthyroidism. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2004;26:172-7.
43. Huang MJ, Li KL, Wei JS, Wu SS, Fan KD, et al. Sequential liver and bone biochemical changes in hyperthyroidism: Prospective controlled follow-up study. Am J Gastroenterol 1994;89:1071-6.
44. Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab 2009;94:1881-2.
45. Ruiz JK, Rossi GV, Vallejos HA, Brenet RW, Lopez IB, et al. Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother 2003;37:224-8.
46. Gotta AW, Sullivan CA, Seaman J, Jean-Gilles B. Prolonged intraoperative bleeding caused by propylthiouracil-induced hypoprothrombinemia. Anesthesiology 1972;37:562-3.
47. Mihas AA, Holley P, Koff RS, Hirschowitz BI. Fulminant hepatitis and lymphocyte sensitization due to propylthiouracil. Gastroenterology 1976;70(Pt 1):770-4.
48. Eisen MJ. Fulminant hepatitis during treatment with propylthiouracil. N Engl J Med 1953;249:814-6.
49. Safani MM, Tatro DS, Rudd P. Fatal propylthiouracil-induced hepatitis. Arch Intern Med 1982;142:838-9.
50. Limaye A, Ruffolo PR. Propylthiouracil-induced fatal hepatic necrosis. Am J Gastroenterol 1987;82:152-4.
51. Weiss M, Hassin D, Bank H. Propylthiouracil-induced hepatic damage. Arch Intern Med 1980;140:1184-5.
52. Fedotin MS, Lefer LG. Liver disease caused by propylthiouracil. Arch Intern Med 1975;135:319-21.
53. Colwell AR Jr, Sando DE, Lang SJ. Propylthiouracil-induced agranulocytosis, toxic hepatitis, and death. J Am Med Assoc 1952;148:639-41.
54. Pacini F, Sridama V, Refetoff S. Multiple complications of propylthiouracil treatment: Granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization. J Endocrinol Invest 1982;5:403-7.
55. Sherlock S, editor. Disorders of the liver and biliary system. Oxford, UK: Blackwell Scientific Publications, 1985.
56. Nagai T, Imamura M, Kamiya Y, Mori M. Graves'disease accompanied by anti-myeloperoxidase antibody-related nephropathy and autoimmune hepatitis. Intern Med 2004;43:516-20.
57. Gürlek A, Cobankara V, Bayraktar M. Liver tests in hyperthyroidism: Effect of antithyroid therapy. J Clin Gastroenterol 1997; 24:180-3.
58. Karras S, Tzotzas T, Krassas GE. Toxicological considerations for antithyroid drugs in children. Expert Opin Drug Metab Toxicol 2011;7:399-410.
59. Dolman KM, Gans RO, Vervaat TJ, Zevenbergen G, Maingay D, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993;342:651-2.
60. Vogt BA, Kim Y, Jennette JC, Falk RJ, Burke BA, et al. Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children. J Pediatr 1994;124:986-8.
61. Wing SS, Fantus IG. Adverse immunologic effects of antithyroid drugs. CMAJ 1987;136:121-7.
62. Sato K, Mimura H, Kato S, Isozaki O, Tsushima T, et al. Serum propylthiouracil concentration in patients with Graves'disease with various clinical course. Acta Endocrinol (Copenh) 1983;104:189-94.
63. Karras S, Tzotzas T, Kaltsas T, Krassas GE. Pharmacological treatment of hyperthyroidism during lactation: Review of the literature and novel data. Pediatr Endocrinol Rev 2010;8:25-33.